Sarepta Therapeutics (SRPT) Tops Q4 EPS by 29c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vifor Pharma said to have confirmed the purchase of Sarepta's (SRPT) Priority Review Voucher - Bloomberg
February 25, 2020 12:14 PM ESTVifor Pharma said to have confirmed the purchase of Sarepta's (NASDAQ: SRPT) Priority Review Voucher, as rumored earlier. - Bloomberg
... MoreSarepta Therapeutics (SRPT) May Have Sold Priority Review Voucher to Vifor - RBC
February 25, 2020 11:03 AM ESTRBC Capital analyst Brian Abrahams said there are signs that Sarepta Therapeutics (NASDAQ: SRPT) sold its Priority Review Voucher to Vifor Pharma.
"... we note a notice emerging just this morning from FTC providing clearance for an undisclosed transaction between SRPT and Vifor... More
